HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rolando Pajon Selected Research

2019-nCoV Vaccine mRNA-1273

6/2023Mapping SARS-CoV-2 antigenic relationships and serological responses.
3/2023Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.
1/2023Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.
1/2023Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19.
1/2023Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial.
11/2022Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial.
11/2022Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
11/2022Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
3/2022Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
1/2022Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rolando Pajon Research Topics

Disease

25COVID-19
03/2023 - 01/2021
8Infections
10/2023 - 01/2006
2Reinfection
01/2021 - 01/2021
1Severe Acute Respiratory Syndrome
03/2022
1COVID-19 related pediatric multisystem inflammatory disease
01/2022
1Myocarditis (Carditis)
01/2022
1Breakthrough Infections
01/2022
1Pericarditis
01/2022
1Headache (Headaches)
12/2021
1Fatigue
12/2021
1Pain (Aches)
12/2021
1Asymptomatic Infections
11/2021
1Meningitis
12/2015
1Sepsis (Septicemia)
12/2015
1Bacteremia
01/2012
1Persistent Infection
01/2012
1Meningococcal Infections
09/2011
1Bacterial Infections (Bacterial Infection)
04/2006

Drug/Important Bio-Agent (IBA)

24VaccinesIBA
03/2023 - 01/2006
222019-nCoV Vaccine mRNA-1273IBA
06/2023 - 01/2021
6Messenger RNA (mRNA)IBA
10/2023 - 01/2021
4Proteins (Proteins, Gene)FDA Link
01/2023 - 09/2011
4Neutralizing AntibodiesIBA
01/2023 - 01/2021
3Immunoglobulins (Immunoglobulin)IBA
12/2021 - 09/2021
2Immunoglobulin G (IgG)IBA
01/2023 - 08/2021
2AntibodiesIBA
01/2023 - 01/2022
1COVID-19 VaccinesIBA
03/2023
1Combined VaccinesIBA
11/2022
1Therapeutic UsesIBA
12/2021
1Monoclonal AntibodiesIBA
12/2021
1Lipid NanoparticlesIBA
01/2021
1Carrier Proteins (Binding Protein)IBA
12/2015
1Complement Factor H (Factor H)IBA
12/2015
1ProteomeIBA
01/2012
1Complement System Proteins (Complement)IBA
01/2012
1Polysaccharides (Glycans)IBA
09/2011
1Conjugate VaccinesIBA
09/2011
1Transferrin (beta 2 Transferrin)IBA
04/2006

Therapy/Procedure

3Injections
12/2021 - 01/2021
2Intramuscular Injections
11/2021 - 01/2021
1Therapeutics
12/2021